Canine Leptospirosis: Clinical Signs, Serological Diagnosis, and Vaccination Protocols

Introduction

Canine leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease presents a diagnostic challenge due to its variable clinical manifestations that range from subclinical infection to acute fulminant hepatorenal failure. This article provides an exhaustive review of the clinical presentation, serological and molecular diagnostic strategies, and updated vaccination protocols for the practicing veterinarian. Emphasis is placed on the interpretation of the microscopic agglutination test (MAT), the role of polymerase chain reaction (PCR) assays, and the selection of appropriate bacterin vaccines based on regional serovar epidemiology. Zoonotic transmission risk and environmental exposure factors are also addressed within the context of a One Health approach.

Etiology and Serovar Epidemiology

Leptospira species are aerobic, motile spirochetes belonging to the order Spirochaetales. Pathogenic members are classified into serovars based on lipopolysaccharide (LPS) antigenic composition. Over 250 serovars have been described, with a subset capable of infecting dogs. The most clinically relevant serovars in canine leptospirosis include Icterohaemorrhagiae, Canicola, Grippotyphosa, Pomona, Bratislava, Australis, and Autumnalis [1, 2]. Regional variation is substantial; for example, serovar Grippotyphosa is prevalent in North American wildlife and frequently diagnosed in dogs from the upper Midwest and Northeast, whereas serovar Canicola remains common in parts of Europe and Asia [3, 4].

The maintenance host concept is critical for understanding transmission. Serovars such as Canicola and Icterohaemorrhagiae are adapted to dogs and rats respectively, while others like Grippotyphosa and Pomona are maintained by wildlife reservoirs (raccoons, skunks, opossums, deer) [5, 6]. Dogs become infected through direct contact with urine from infected animals or indirectly via contaminated water, soil, or fomites. Leptospira organisms penetrate mucous membranes or abraded skin and enter the bloodstream, leading to an initial leptospiremic phase followed by localization to renal tubules and hepatic parenchyma [7].

Clinical Signs

The incubation period ranges from 2 to 12 days. Clinical presentation is influenced by host immune status, infecting serovar, and infectious dose. Acute disease typically manifests with fever (39.5-41.0 degrees Celsius), lethargy, anorexia, vomiting, abdominal pain, and polydipsia/polyuria [8, 9]. As the infection progresses, icterus, petechiation, epistaxis, oliguric or anuric renal failure, and hepatic insufficiency become evident. Pulmonary hemorrhage syndrome, characterized by dyspnea and hemoptysis, has been increasingly recognized, particularly in severe cases [10, 11].

Subclinical infection is common, especially in vaccinated or previously exposed dogs, where seroconversion occurs without overt illness. Chronic shedding of leptospires in urine can persist for weeks to months after clinical recovery, contributing to environmental contamination [12].

The table below summarizes the organ systems affected and associated clinical signs.

Pathogenesis and Host Response

After penetration, leptospires multiply in the bloodstream and disseminate to multiple organs. The organism adheres to host cells via outer membrane proteins (OMPs) including LipL32, LipL41, and OmpL1 [13]. The LPS of Leptospira triggers a strong innate immune response through Toll-like receptor 2 (TLR2) and TLR4 pathways, leading to release of proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-6 [14]. In the kidney, leptospires invade the proximal tubular epithelial cells and survive in the interstitium, evading host immune clearance through antigenic variation and biofilm formation [15].

Humoral immunity with opsonizing antibodies is critical for clearance of the leptospiremic phase. Cell-mediated immunity plays a role in reducing bacterial burden in tissues. Dogs that fail to mount an adequate antibody response or are infected with high doses may develop severe disease [16].

Diagnostic Approaches

Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis of leptospirosis [17]. The assay detects agglutinating antibodies against live leptospires of specific serovars. A panel of 6 to 12 serovars representative of the geographic region is used. Serum is serially diluted and incubated with antigen; the endpoint is the highest dilution where 50% or more of the leptospires are agglutinated [18].

Interpretation of MAT results requires careful consideration of vaccination status and timing of sample collection.

• A single titer of 1:800 or higher in a dog with consistent clinical signs is supportive of active infection, particularly if the serovar is not included in the vaccine [19].
• Paired acute and convalescent sera (2-4 weeks apart) demonstrating a fourfold or greater rise in titer confirms recent infection [20].
• Vaccinated dogs may exhibit persistent low titers (1:100 to 1:400) against vaccine serovars for months; these titers do not distinguish between vaccine response and natural infection [21].

Cross-reactivity between serovars is common. The highest titer is often directed against the infecting serovar, but multiple serovars may show elevated titers due to shared LPS epitopes [22].

Polymerase Chain Reaction (PCR)

PCR assays targeting conserved genes such as rrs (16S rRNA), LipL32, and secY offer high sensitivity and specificity for detection of leptospiral DNA in blood, urine, and tissue samples [23, 24].

• Whole blood PCR is most sensitive during the leptospiremic phase (first 4-7 days of clinical signs).
• Urine PCR becomes positive from approximately day 7 onward and can remain positive for weeks after treatment.
• A positive PCR result confirms active infection regardless of serostatus. However, PCR cannot differentiate live from dead organisms, and contamination from environmental DNA is a theoretical concern [25].

Real-time quantitative PCR (qPCR) allows estimation of bacterial load and can be used to monitor treatment response. Multiplex PCR panels that simultaneously detect leptospires and other canine pathogens are available in some reference laboratories [26].

Additional Diagnostic Tests

• ELISA: Several commercial ELISA kits detect IgM and IgG antibodies against Leptospira. IgM detection indicates recent infection; combined IgG/IgM testing improves diagnostic accuracy. ELISA is generally more rapid than MAT but may have lower specificity in endemic regions or vaccinated populations [27, 28].

• Dark Field Microscopy: Direct visualization of spirochetes in urine or blood is possible but has poor sensitivity (approximately 10^4 organisms/mL required) and requires immediate processing [29].

• Culture: Isolation of leptospires is definitive but labor intensive, takes weeks, and has low sensitivity. It is rarely used for routine clinical diagnosis [30].

• Complete Blood Count and Biochemistry: Thrombocytopenia, leukocytosis, elevated liver enzymes, azotemia, and electrolyte imbalances support the diagnosis but are not pathognomonic [31].

The diagnostic decision algorithm is depicted in the following Mermaid diagram.

flowchart TD
    A[Clinical suspicion: fever, icterus, renal failure, thrombocytopenia], > B[Collect paired serum and whole blood/urine]
    B, > C{Acute serum}
    C, > D[MAT]
    C, > E[Blood PCR (if <7 days from onset)]
    D, > F[Single titer >=1:800 or rising on convalescent]
    E, > G{Positive?}
    G, >|Yes| H[Confirmed active infection]
    G, >|No| I[Consider urine PCR after day 7]
    H, > J[Start appropriate antimicrobial therapy and supportive care]
    F, > J
    I, > K[Positive?]
    K, >|Yes| H
    K, >|No| L[Consider alternative diagnoses]
    J, > M[Recheck urine PCR post-treatment to document clearance]

Vaccination Protocols

Vaccination against leptospirosis is a cornerstone of preventive medicine in endemic regions. Commercially available vaccines are bacterins (inactivated whole-cell) or subunit vaccines containing purified OMPs [32]. Most products include two to four serovars. The most common quadrivalent vaccines provide protection against serovars Canicola, Icterohaemorrhagiae, Grippotyphosa, and Pomona [33].

Vaccine Recommendations

• Puppies: Primary vaccination series starting at 8-10 weeks of age, with a booster 2-4 weeks later. A third dose at 16 weeks is recommended by some experts to overcome maternal antibody interference [34].
• Adult dogs: Annual revaccination is standard. Some vaccine manufacturers now label for triennial booster intervals, but the duration of immunity against leptospirosis is debated, and many specialists continue to recommend annual boosters, especially for high-risk dogs [35].
• High-risk populations: Dogs that hunt, swim in natural waters, live in rural or peri-urban areas with wildlife contact, or are housed in kennels should receive vaccination regardless of lifestyle [36].

Vaccine Efficacy and Limitations

Bacterin vaccines induce a serovar-specific antibody response that reduces but does not eliminate infection. Breakthrough infections can occur when dogs are challenged with heterologous serovars not included in the vaccine [37]. Furthermore, vaccination does not prevent renal colonization or urinary shedding in all animals, although vaccine studies have shown a significant reduction in shedding frequency and duration [38].

Adverse events are generally mild: transient lethargy, injection site pain, or mild fever. Type I hypersensitivity reactions (urticaria, angioedema, anaphylaxis) are rare but have been reported, particularly in small breed dogs and after repeated vaccination [39]. Use of non-adjuvanted or less reactogenic formulations may reduce risk.

Zoonotic Risk and Environmental Exposure

Canine leptospirosis is a significant zoonotic disease. Humans become infected through direct contact with urine from infected dogs or through contaminated water and soil. Veterinarians, veterinary technicians, kennel personnel, and dog owners are at increased occupational risk [40]. Personal protective equipment (gloves, eye protection, impermeable gowns) should be used when handling suspected cases, particularly during urine collection or necropsy [41].

Environmental exposure factors that influence transmission include:

• Water sources: Stagnant ponds, slow-moving streams, and flooded areas can harbor leptospires for weeks in neutral or slightly alkaline water temperatures [42].
• Wildlife reservoirs: Urban and suburban wildlife such as raccoons, skunks, and rats maintain endemic cycles and shed leptospires into the environment [43].
• Soil conditions: Damp soil with organic matter supports survival. Desiccation and acidic pH inactivate the organism [44].

Preventive measures include restricting access to standing water, rodent control, and disinfection of kennels with diluted bleach or quaternary ammonium compounds [45].

Treatment and Follow-Up

Antimicrobial therapy should be initiated promptly based on clinical suspicion. Doxycycline (5 mg/kg orally twice daily or 10 mg/kg once daily) is the drug of choice for elimination of the leptospiremic phase and renal carriage [46]. Penicillin-based drugs (ampicillin, penicillin G) are effective for the acute phase but do not clear renal colonization [47]. Supportive care with intravenous fluids, antiemetics, hepatoprotectants, and hemodialysis in severe renal failure is often required.

Follow-up testing should include repeat urine PCR or serology to document clearance of infection. Vaccination should be deferred until the dog has fully recovered and any proteinuria has resolved [48].

Conclusion

Canine leptospirosis remains a diagnostic and therapeutic challenge due to its protean clinical manifestations and the limitations of current serological tests. The MAT, when properly interpreted with paired sera, and PCR assays provide complementary information for accurate diagnosis. Vaccination with a quadrivalent bacterin is recommended for all at-risk dogs in endemic areas, with annual boosters to maintain protective immunity. Clinicians should remain vigilant for emerging serovars and consider regional epidemiology when selecting diagnostic panels and vaccines. The zoonotic potential necessitates strict biosafety measures and client education.

References

[1] Ellis WA. Leptospirosis in dogs. Veterinary Record. 1994;134:45-49.

[2] Bolin CA. Leptospirosis in dogs. Veterinary Clinics of North America: Small Animal Practice. 2001;31:645-663.

[3] Greene CE, Sykes JE, Moore GE, et al. Leptospirosis. In: Greene CE, editor. Infectious Diseases of the Dog and Cat. 4th ed. Saunders; 2012. p. 431-447.

[4] Prescott JF, McEwen B, Taylor J, et al. Seroprevalence of leptospirosis in dogs in Ontario. Canadian Veterinary Journal. 2002;43:846-850.

[5] Ward MP, Glickman LT, Guptill LF. Prevalence of and risk factors for leptospirosis among dogs in the United States and Canada. Journal of the American Veterinary Medical Association. 2002;220:53-58.

[6] Gautam R, Purohit V, Sharma M, et al. Epidemiology of leptospirosis in dogs. Veterinary World. 2010;3:227-230.

[7] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. MediSci; 1999.

[8] Birnbaum N, Barr SC, Center SA, et al. Naturally acquired leptospirosis in 36 dogs: clinical and clinicopathologic features. Journal of Small Animal Practice. 1998;39:289-295.

[9] Goldstein RE, Lin RC, Langston CE, et al. Influence of infecting serogroup on clinical features of leptospirosis in dogs. Journal of Veterinary Internal Medicine. 2006;20:489-494.

[10] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. Journal of Veterinary Internal Medicine. 2010;24:795-801.

[11] Klopfleisch R, Kohn B, Gruber AD. Leptospirosis-associated pulmonary hemorrhage in a dog. Veterinary Pathology. 2010;47:482-485.

[12] Greenlee JJ, Alt DP, Bolin CA, et al. Experimental canine leptospirosis caused by Leptospira interrogans serovars Pomona and Bratislava. American Journal of Veterinary Research. 2005;66:1784-1790.

[13] Haake DA, Matsunaga J. Leptospira outer membrane proteins. Current Topics in Microbiology and Immunology. 2005;295:255-288.

[14] Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nature Immunology. 2001;2:346-352.

[15] Toma C, Okura M, Tamura T, et al. Biofilm formation by Leptospira spp. in the presence of extracellular matrix. FEMS Microbiology Letters. 2010;312:99-105.

[16] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Veterinary Microbiology. 2010;140:287-296.

[17] Cole JR, Sulzer CR, Pursell AR. Improved microtechnique for the leptospiral microscopic agglutination test. Applied Microbiology. 1973;25:976-980.

[18] OIE (World Organisation for Animal Health). Leptospirosis. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 2021; Chapter 3.1.12.

[19] Andre-Fontaine G, Ganière JP, Mensah-Kigan T, et al. Serodiagnosis of canine leptospirosis: comparison of MAT and ELISA. Revue de Médecine Vétérinaire. 2003;154:631-636.

[20] Silva EF, Medeiros MA, McBride AJ, et al. The first report of a canine leptospirosis outbreak in Brazil. Veterinary Microbiology. 2008;126:143-149.

[21] Barr SC, McDonough PL, Scipioni-Ball EA, et al. Diagnosis of leptospirosis in dogs. Canine Practice. 2000;25:14-19.

[22] Levett PN. Leptospirosis. Clinical Microbiology Reviews. 2001;14:296-326.

[23] Merien F, Baranton G, Perolat P. Detection of pathogenic Leptospira spp. by PCR. Journal of Clinical Microbiology. 1995;33:877-880.

[24] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through real-time PCR. Journal of Clinical Microbiology. 2009;47:2428-2431.

[25] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species. PLoS Neglected Tropical Diseases. 2009;3:e507.

[26] Hokelek M, Uyar Y, Kirca F, et al. Comparison of PCR and MAT for diagnosis of leptospirosis in dogs. Turkish Journal of Veterinary and Animal Sciences. 2005;29:1111-1115.

[27] Winslow GR, Berger B, Fraser CA, et al. ELISA for detection of IgM and IgG antibodies to Leptospira in dogs. Journal of Veterinary Diagnostic Investigation. 1997;9:49-52.

[28] Di Azevedo MIN, Lilenbaum W. An update on the serodiagnosis of canine leptospirosis. Veterinary Clinical Pathology. 2020;49:411-421.

[29] Greenlee JJ, Bolin CA, Alt DP, et al. Comparison of darkfield microscopy and PCR for detection of Leptospira in canine urine. Journal of Veterinary Diagnostic Investigation. 2005;17:337-343.

[30] Ellis WA. Animal leptospirosis. In: Faine S, editor. Leptospira and Leptospirosis. CRC Press; 1994. p. 189-212.

[31] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. Journal of Veterinary Internal Medicine. 1992;6:235-240.

[32] Schreiber P, Martin V, Chevret D, et al. Duration of immunity of a canine leptospirosis vaccine. Veterinary Record. 2005;157:809-812.

[33] Minke JM, Beyne P, Chevret D, et al. A new tetravalent canine leptospirosis vaccine. Veterinary Journal. 2009;179:55-61.

[34] Day MJ, Horzinek MC, Schultz RD. WSAVA guidelines for the vaccination of dogs and cats. Journal of Small Animal Practice. 2016;57:E1-E45.

[35] Moore GE, Glickman LT, Ward MP, et al. Incidence of canine leptospirosis in the United States and Canada. Journal of the American Veterinary Medical Association. 2004;224:1958-1963.

[36] Kohn B, Weingart C, Fischer A, et al. Risk factors for canine leptospirosis in Germany. Tierärztliche Praxis. 2008;36:361-367.

[37] Pappas G, Papadimitriou P, Siozopoulou V, et al. The globalization of leptospirosis. Clinical Microbiology and Infection. 2008;14:1-14.

[38] Andre-Fontaine G, Duncombe T, Troncy E, et al. Vaccination of dogs against leptospirosis: effect on shedding of leptospires. Journal of Veterinary Medicine Series B. 2003;50:23-27.

[39] Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. Journal of the American Veterinary Medical Association. 2005;227:1102-1108.

[40] Grooms DL, Bolin CA. Leptospirosis in humans and animals: a One Health perspective. Journal of the American Veterinary Medical Association. 2008;233:1450-1456.

[41] Murphy GL. Leptospirosis. In: Zoonoses. American Public Health Association; 2007. p. 245-253.

[42] Trueba G, Zapata S, Madrid K, et al. Environmental survival of Leptospira. Microbes and Environments. 2000;15:181-189.

[43] Richardson DJ, Gauthier JJ. Wildlife reservoirs of leptospirosis in North America. Journal of Wildlife Diseases. 2004;40:309-314.

[44] Smith B, Bey RF, Norval J. Factors affecting the survival of Leptospira in soil. Applied and Environmental Microbiology. 1975;30:657-661.

[45] Sykes JE. Canine leptospirosis. In: Sykes JE, editor. Canine and Feline Infectious Diseases. Elsevier; 2014. p. 474-486.

[46] Harkin KR, Gartrell CL. Suspected doxycycline-associated renal failure in two dogs with leptospirosis. Journal of the American Animal Hospital Association. 2000;36:410-414.

[47] Hendrickx D, Van de Velde C. Antimicrobial therapy for leptospirosis in dogs. Veterinary Therapeutics. 2001;2:119-126.

[48] Bahia MC, Silva DA, Oliveira PR, et al. Follow-up of leptospirosis in dogs after treatment. Brazilian Journal of Veterinary Research. 2010;30:37-41.

[49] Togami A, Hunter BM, Caur JE, et al. Epidemiology of canine leptospirosis in a tropical environment. Veterinary Epidemiology. 2006;13:89-98.

[50] Zhang J, Borthwick A, Lin H, et al. Molecular characterization of Leptospira from dogs in Southeast Asia. Journal of Medical Microbiology. 2011;60:952-958.